Cargando…
Nilotinib in Parkinson's disease: A systematic review and meta-analysis
BACKGROUND: Nilotinib, which inhibits cellular Abelson tyrosine kinase, may be an effective treatment for patients with Parkinson's disease (PD). The purpose of this study is to evaluate the outcomes of different doses of nilotinib in patients with PD. METHODS: We searched PubMed, Embase, Web o...
Autores principales: | Xie, Xiaolu, Yuan, Ping, Kou, Liqiu, Chen, Xiu, Li, Jun, Li, Yaling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558096/ https://www.ncbi.nlm.nih.gov/pubmed/36248007 http://dx.doi.org/10.3389/fnagi.2022.996217 |
Ejemplares similares
-
Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis
por: Wang, Ke, et al.
Publicado: (2023) -
Efficacy of Tai Chi on lower limb function of Parkinson’s disease patients: A systematic review and meta-analysis
por: Zhu, Ping-an, et al.
Publicado: (2023) -
Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
por: Chen, Xiu, et al.
Publicado: (2023) -
Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: A systematic review and meta-analysis
por: Kou, Liqiu, et al.
Publicado: (2022) -
Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
por: Chen, Xiu, et al.
Publicado: (2023)